应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
RVMD Revolution Medicines, Inc.
交易中 04-06 10:27:08 EDT
97.27
-1.85
-1.87%
最高
98.73
最低
97.18
成交量
23.93万
今开
98.19
昨收
99.12
日振幅
1.57%
总市值
192.75亿
流通市值
174.10亿
总股本
1.98亿
成交额
2,344万
换手率
0.13%
流通股本
1.79亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Revolution Medicines启动Rasolute 303三期临床试验，评估Daraxonrasib作为转移性胰腺癌一线疗法
美股速递 · 04-02
Revolution Medicines启动Rasolute 303三期临床试验，评估Daraxonrasib作为转移性胰腺癌一线疗法
Revolution Medicines公布2025年第四季度及全年财务业绩，并更新企业进展
美股速递 · 02-26
Revolution Medicines公布2025年第四季度及全年财务业绩，并更新企业进展
Revolution Medicines公司：Rasolute 302三期试验数据将于2026年上半年揭晓，评估Daraxonrasib用于二线转移性PDAC
美股速递 · 02-26
Revolution Medicines公司：Rasolute 302三期试验数据将于2026年上半年揭晓，评估Daraxonrasib用于二线转移性PDAC
Revolution Medicines Inc C/Wts 17/12/2026 (To Pur Com)盘中异动 大幅上涨5.26%报1.80美元
市场透视 · 02-18
Revolution Medicines Inc C/Wts 17/12/2026 (To Pur Com)盘中异动 大幅上涨5.26%报1.80美元
Revolution Medicines Inc C/Wts 17/12/2026 (To Pur Com)盘中异动 大幅下跌8.39%
市场透视 · 02-11
Revolution Medicines Inc C/Wts 17/12/2026 (To Pur Com)盘中异动 大幅下跌8.39%
瑞孚迪携手礼来，拓展AI药物发现模型的可及性
仪器网 · 02-05
瑞孚迪携手礼来，拓展AI药物发现模型的可及性
Revolution Medicines Inc C/Wts 17/12/2026 (To Pur Com)盘中异动 急速拉升6.67%
市场透视 · 02-03
Revolution Medicines Inc C/Wts 17/12/2026 (To Pur Com)盘中异动 急速拉升6.67%
Revolution Medicines启动RMC-5127临床试验 首位患者完成给药
美股速递 · 01-29
Revolution Medicines启动RMC-5127临床试验 首位患者完成给药
Revolution Medicines Inc C/Wts 17/12/2026 (To Pur Com)盘中异动 大幅下挫5.64%
市场透视 · 01-27
Revolution Medicines Inc C/Wts 17/12/2026 (To Pur Com)盘中异动 大幅下挫5.64%
默沙东300亿美元收购谈判搁浅！
药时代 · 01-26
默沙东300亿美元收购谈判搁浅！
默沙东终止收购Revolution Medicines的谈判
环球市场播报 · 01-26
默沙东终止收购Revolution Medicines的谈判
默克终止收购谈判消息传出 Revolution Medicines盘前股价暴跌20.7%
美股速递 · 01-26
默克终止收购谈判消息传出 Revolution Medicines盘前股价暴跌20.7%
300亿美元生物医药并购告吹？默克转身离场，Revolution降温但故事未完
金融界 · 01-26
300亿美元生物医药并购告吹？默克转身离场，Revolution降温但故事未完
夜盘异动 | Revolution重挫19%，300亿美元天价收购告吹！默沙东与Revolution因价格分歧中止谈判
智通财经 · 01-26
夜盘异动 | Revolution重挫19%，300亿美元天价收购告吹！默沙东与Revolution因价格分歧中止谈判
Revolution Medicines Inc C/Wts 17/12/2026 (To Pur Com)盘中异动 早盘股价大跌6.25%报3.00美元
市场透视 · 01-12
Revolution Medicines Inc C/Wts 17/12/2026 (To Pur Com)盘中异动 早盘股价大跌6.25%报3.00美元
默沙东关注RVMD 艾伯维否认兴趣
环球市场播报 · 01-10
默沙东关注RVMD 艾伯维否认兴趣
盘前异动｜无人机概念股延续涨势，AgEagle涨超12%；Revolution涨超13%，传默沙东正就洽谈收购该公司
老虎资讯综合 · 01-09
盘前异动｜无人机概念股延续涨势，AgEagle涨超12%；Revolution涨超13%，传默沙东正就洽谈收购该公司
传获默沙东洽谈收购癌症药物开发商Revolution，交易价格或达320亿美元
智通财经 · 01-09
传获默沙东洽谈收购癌症药物开发商Revolution，交易价格或达320亿美元
美股异动｜Revolution Medicines夜盘涨超13%，传获默沙东以至多320亿美元报价洽购
格隆汇 · 01-09
美股异动｜Revolution Medicines夜盘涨超13%，传获默沙东以至多320亿美元报价洽购
美股夜盘 | OPEN涨近15%， 英特尔涨近2%；RVMD涨超15%，据报默沙东正就洽谈收购
老虎资讯综合 · 01-09
美股夜盘 | OPEN涨近15%， 英特尔涨近2%；RVMD涨超15%，据报默沙东正就洽谈收购
加载更多
公司概况
公司名称：
Revolution Medicines, Inc.
所属市场：
NASDAQ
上市日期：
--
主营业务：
Revolution Medicines, Inc.成立于2014年10月，是特拉华州的一家公司。该公司是一家临床阶段的精准肿瘤学公司，专注于开发靶向疗法，以抑制RAS成瘾癌症的前沿靶点。该公司拥有先进的基于结构的药物发现能力，其基础是深厚的化学生物学和癌症药理学知识以及创新的专有技术，能够创造适合非常规结合位点的小分子。该公司对癌症的遗传驱动因素和适应性耐药机制的了解，加上强大的药物发现和药物化学能力，指导建立了一个针对RAS通路和相关通路中的关键信号节点的深层管道。
发行价格：
--
{"stockData":{"symbol":"RVMD","market":"US","secType":"STK","nameCN":"Revolution Medicines, Inc.","latestPrice":97.265,"timestamp":1775485625084,"preClose":99.12,"halted":0,"volume":239342,"delay":0,"changeRate":-0.018714689265536762,"floatShares":179000000,"shares":198173397,"eps":-5.95,"marketStatus":"交易中","change":-1.855,"latestTime":"04-06 10:27:08 EDT","open":98.19,"high":98.73,"low":97.175,"amount":23436024.944888,"amplitude":0.015688,"askPrice":97.43,"askSize":200,"bidPrice":97.32,"bidSize":3,"shortable":3,"etf":0,"ttmEps":-5.95,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1775505600000},"marketStatusCode":2,"adr":0,"listingDate":1581570000000,"exchange":"NASDAQ","adjPreClose":99.12,"preHourTrading":{"tag":"盘前","latestPrice":99.5,"preClose":99.12,"latestTime":"09:21 EDT","volume":147,"amount":14645.998814999999,"timestamp":1775481693690,"change":0.38,"changeRate":0.003834,"amplitude":0.005044},"postHourTrading":{"tag":"盘后","latestPrice":99.12,"preClose":99.12,"latestTime":"19:50 EDT","volume":53369,"amount":5289821.92,"timestamp":1775173841268,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.83688,"impliedVol":1.0996,"impliedVolPercentile":0.984},"requestUrl":"/m/hq/s/RVMD","defaultTab":"news","newsList":[{"id":"1198800251","title":"Revolution Medicines启动Rasolute 303三期临床试验，评估Daraxonrasib作为转移性胰腺癌一线疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1198800251","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198800251?lang=zh_cn&edition=full","pubTime":"2026-04-02 20:02","pubTimestamp":1775131343,"startTime":"0","endTime":"0","summary":"Revolution Medicines, Inc. (RVMD) 已正式启动Rasolute 303三期临床试验的患者给药工作，该项研究旨在评估其核心候选药物Daraxonrasib作为转移性胰腺癌患者一线治疗方案的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191280929","title":"Revolution Medicines公布2025年第四季度及全年财务业绩，并更新企业进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1191280929","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191280929?lang=zh_cn&edition=full","pubTime":"2026-02-26 05:03","pubTimestamp":1772053419,"startTime":"0","endTime":"0","summary":"Revolution Medicines, Inc.近日披露了其2025财年第四季度及全年的财务业绩报告，同时向市场更新了公司在研发及业务运营方面的最新进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198767156","title":"Revolution Medicines公司：Rasolute 302三期试验数据将于2026年上半年揭晓，评估Daraxonrasib用于二线转移性PDAC","url":"https://stock-news.laohu8.com/highlight/detail?id=1198767156","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198767156?lang=zh_cn&edition=full","pubTime":"2026-02-26 05:03","pubTimestamp":1772053407,"startTime":"0","endTime":"0","summary":"Revolution Medicines公司宣布，其针对Daraxonrasib在二线转移性胰腺导管腺癌（PDAC）患者中开展的Rasolute 302三期临床试验，正按计划稳步推进。关键试验数据的读取时间点预计在2026年上半年。这一进展标志着公司在靶向RAS通路创新疗法开发上的重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612428076","title":"Revolution Medicines Inc C/Wts 17/12/2026 (To Pur Com)盘中异动 大幅上涨5.26%报1.80美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612428076","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612428076?lang=zh_cn&edition=full","pubTime":"2026-02-18 23:17","pubTimestamp":1771427869,"startTime":"0","endTime":"0","summary":"北京时间2026年02月18日23时17分，Revolution Medicines Inc C/Wts 17/12/2026 股票出现异动，股价急速拉升5.26%。Revolution Medicines Inc C/Wts 17/12/2026 股票所在的生物技术行业中，整体跌幅为0.34%。Revolution Medicines Inc C/Wts 17/12/2026 公司简介：Revolution Medicines Inc是一家临床阶段的精密肿瘤学公司，致力于开发新颖的靶向疗法，以抑制臭名昭著的生长和生存途径内的难以捉摸的前沿靶标，尤其侧重于RAS和mTOR信号通路。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021823174995416a31&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021823174995416a31&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RVMDW","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610913513","title":"Revolution Medicines Inc C/Wts 17/12/2026 (To Pur Com)盘中异动 大幅下跌8.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610913513","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610913513?lang=zh_cn&edition=full","pubTime":"2026-02-11 22:58","pubTimestamp":1770821883,"startTime":"0","endTime":"0","summary":"北京时间2026年02月11日22时58分，Revolution Medicines Inc C/Wts 17/12/2026 股票出现波动，股价快速下跌8.39%。Revolution Medicines Inc C/Wts 17/12/2026 股票所在的生物技术行业中，整体跌幅为0.91%。Revolution Medicines Inc C/Wts 17/12/2026 公司简介：Revolution Medicines Inc是一家临床阶段的精密肿瘤学公司，致力于开发新颖的靶向疗法，以抑制臭名昭著的生长和生存途径内的难以捉摸的前沿靶标，尤其侧重于RAS和mTOR信号通路。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211225803a498901d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211225803a498901d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RVMDW","RVMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609377075","title":"瑞孚迪携手礼来，拓展AI药物发现模型的可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=2609377075","media":"仪器网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609377075?lang=zh_cn&edition=full","pubTime":"2026-02-05 09:45","pubTimestamp":1770255930,"startTime":"0","endTime":"0","summary":"近日，瑞孚迪宣布与礼来达成合作，通过在瑞孚迪Signals平台引入礼来TuneLab，进一步扩大礼来高质量预测模型的应用覆盖面。产品，旨在构建一个可扩展的联合框架，从而加速AI赋能的药物发现。依托瑞孚迪的Models-as-a-Service架构以及Signals Xynthetica平台，参与机构可将礼来的预测模型直接应用于自身药物发现项目，同时确保其专有数据始终保持私密与安全。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205094903a47dea14&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205094903a47dea14&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0004445015.USD","LU2265009873.SGD","LU0256863902.USD","RVMD","LU2237443382.USD","LU2357305700.SGD","LU1093756325.SGD","IE0004445239.USD","LU2471134879.HKD","BK4581","LU1023059063.AUD","IE00B1BXHZ80.USD","LU0316494557.USD","LU0432979614.USD","LU0820561818.USD","LU1064131342.USD","LU0114720955.EUR","LU1548497426.USD","LU1974910355.USD","LU1983299246.USD","LU2237443622.USD","LU0079474960.USD","LU0823416689.USD","LU0203201768.USD","LU1814569148.SGD","LU2746668461.USD","IE00BFSS7M15.SGD","LU1868836591.USD","LU2168564065.EUR","LU1323610961.USD","LU1868836914.USD","LU0198837287.USD","IE00BK4W5L77.USD","LU1720051017.SGD","LU1712237335.SGD","LU1093756168.USD","LU2168564495.EUR","SG9999013999.USD","LU0225283273.USD","BK4599","BK4585","LU2237438978.USD","LU2750360641.GBP","IE00BJLML261.HKD","LU1623119135.USD","LU1868836757.USD","LU2471134796.USD","LU0823434583.USD","LU0882574055.USD","LU1035775433.USD","LU2211815571.USD","BK4588","LU2237443465.HKD","LU0122379950.USD","LU1720051108.HKD","IE00BKPKM429.USD","LU0106261372.USD","LU2360106947.USD","LU1989771016.USD","LU2462157665.USD","LU2264538146.SGD","LU1551013342.USD","SG9999001176.SGD","LU2236285917.USD","LU2491050154.USD","IE00BJJMRY28.SGD","LU0203202063.USD","LU2896262040.SGD","LU2552382058.USD","LU2552382132.HKD","SG9999015978.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0943347566.SGD","SG9999015945.SGD","SGXZ31699556.SGD","SG9999015952.SGD","LU2271345857.HKD","LU2746668974.SGD","LU2023251221.USD","LU0353189680.USD","LU0683600562.USD","IE0002141913.USD","IE00BKDWB100.SGD","LU2456880835.USD","SGXZ51526630.SGD","LU1061106388.HKD","LU1917777945.USD","LU2023250504.SGD","LU2361045086.USD","LU0256863811.USD","IE00B4JS1V06.HKD","LU0158827948.USD","LU1291159041.SGD","LU0323591593.USD","LU0456855351.SGD","IE00BJJMRX11.SGD","SGXZ99366536.SGD","LU2237443549.SGD","LU0471298694.HKD","LU2112291526.USD","IE00B4R5TH58.HKD","LU2417539215.USD","SG9999014880.SGD","LU2471134952.CNY","LU0266013472.USD","LU0689472784.USD","IE00B1XK9C88.USD","IE0009355771.USD","LU0417517546.SGD","LU0466842654.USD","LU2468319806.SGD","LU2602419157.SGD","LU0320765992.SGD","LU1232071149.USD","LU2108987350.USD","LU2552382215.SGD","LU0096364046.USD","LU0385154629.USD","LU0238689110.USD","BK4533","LU2111349929.HKD","IE00BK4W5M84.HKD","LU0471298777.SGD","IE0005OL40V9.USD","LU2028103732.USD","GB00BDT5M118.USD","IE00B7KXQ091.USD","LU2324357040.USD","LU2089283258.USD","LU2491050071.SGD","LU0109394709.USD","LU1069344957.HKD","LU2491049909.HKD","LU0786609619.USD","LU0672654240.SGD","LU1127390331.HKD","LU2361044949.HKD","LU0109391861.USD","LU1551013425.SGD","LU1267930730.SGD","BK4534","IE00BN29S564.USD","LU0823434740.USD","LU2168563687.JPY","LU1280957306.USD","LU0354030438.USD","LU2089284900.SGD","LU0234572021.USD","LU0006306889.USD","LU0820561909.HKD","LU1988902786.USD","LU1804176565.USD","LU2461242641.AUD","SG9999014898.SGD","LU0061475181.USD","SG9999015986.USD","LU0889565916.HKD","LU1057294990.SGD","LU2361044865.SGD","SG9999014914.USD","LU0094547139.USD","LU1868837300.USD","LU2750360997.AUD","SGXZ81514606.USD","SG9999014906.USD","LU2089984988.USD","LU2471134523.USD","LU2168564149.EUR","LU0158827781.USD","LU0097036916.USD","LU2168564222.USD","BK4007","LLY","IE00B775H168.HKD","LU0210536198.USD","LU0353189763.USD","IE00BWXC8680.SGD","LU0882574139.USD","LU0058720904.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","SG9999018857.SGD","LU0787776722.HKD","LU2237443978.SGD","SG9999018865.SGD","LU0289739699.SGD","LU2237443895.HKD","LU0708995401.HKD","LU0354030511.USD","SGXZ57979304.SGD","IE00BFSS8Q28.SGD","LU0640476718.USD","LU2106854487.HKD","SG9999017495.SGD","LU1366192091.USD","LU2087625088.SGD","LU0320765059.SGD","LU2063271972.USD","SG9999001176.USD","LU1868837136.USD","BK4516"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2608931804","title":"Revolution Medicines Inc C/Wts 17/12/2026 (To Pur Com)盘中异动 急速拉升6.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608931804","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608931804?lang=zh_cn&edition=full","pubTime":"2026-02-03 22:33","pubTimestamp":1770129194,"startTime":"0","endTime":"0","summary":"北京时间2026年02月03日22时33分，Revolution Medicines Inc C/Wts 17/12/2026 股票出现异动，股价急速上涨6.67%。Revolution Medicines Inc C/Wts 17/12/2026 股票所在的生物技术行业中，整体涨幅为0.36%。Revolution Medicines Inc C/Wts 17/12/2026 公司简介：Revolution Medicines Inc是一家临床阶段的精密肿瘤学公司，致力于开发新颖的靶向疗法，以抑制臭名昭著的生长和生存途径内的难以捉摸的前沿靶标，尤其侧重于RAS和mTOR信号通路。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203223315a6cef680&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203223315a6cef680&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RVMD","BK4139","RVMDW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196401919","title":"Revolution Medicines启动RMC-5127临床试验 首位患者完成给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1196401919","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196401919?lang=zh_cn&edition=full","pubTime":"2026-01-29 21:07","pubTimestamp":1769692053,"startTime":"0","endTime":"0","summary":"Revolution Medicines, Inc. (简称：Revolution Medicines) 宣布，其针对RAS(ON) G12V选择性抑制剂RMC-5127的临床试验已正式启动，首位患者成功完成给药。该抑制剂旨在精准靶向特定的RAS基因突变，为相关癌症治疗提供新的潜在方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606773021","title":"Revolution Medicines Inc C/Wts 17/12/2026 (To Pur Com)盘中异动 大幅下挫5.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606773021","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606773021?lang=zh_cn&edition=full","pubTime":"2026-01-27 22:32","pubTimestamp":1769524326,"startTime":"0","endTime":"0","summary":"北京时间2026年01月27日22时32分，Revolution Medicines Inc C/Wts 17/12/2026 股票出现波动，股价急速下挫5.64%。Revolution Medicines Inc C/Wts 17/12/2026 股票所在的生物技术行业中，整体涨幅为0.63%。Revolution Medicines Inc C/Wts 17/12/2026 公司简介：Revolution Medicines Inc是一家临床阶段的精密肿瘤学公司，致力于开发新颖的靶向疗法，以抑制臭名昭著的生长和生存途径内的难以捉摸的前沿靶标，尤其侧重于RAS和mTOR信号通路。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127223206a6b38189&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127223206a6b38189&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RVMD","RVMDW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606703942","title":"默沙东300亿美元收购谈判搁浅！","url":"https://stock-news.laohu8.com/highlight/detail?id=2606703942","media":"药时代","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606703942?lang=zh_cn&edition=full","pubTime":"2026-01-26 19:22","pubTimestamp":1769426529,"startTime":"0","endTime":"0","summary":"据知情人士透露，默沙东与Revolution的收购谈判已暂时停止，核心分歧在于价格。2026年1月7日，市场传出艾伯维拟超200亿美元收购Revolution，后者股价受此消息影响单日涨超28%。尽管艾伯维迅速下场否认，但随后又传出默沙东加入竞逐，并将估值预期大幅抬升至300亿美元区间。该药2024年贡献了公司近半收入、累计销售超1500亿美元的“现金牛”，一旦专利到期，将留下巨额收入缺口。结语默沙东与Revolution的300亿美元博弈虽暂告段落，但风暴眼并未消散。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126221805a6aebc1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126221805a6aebc1d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B4R5TH58.HKD","LU1066051811.HKD","SG9999015341.SGD","LU1066051498.USD","LU2361044949.HKD","MRK","LU1069347547.HKD","LU1093756325.SGD","LU0211331839.USD","LU2112291526.USD","BK4007","IE00BJT1NW94.SGD","LU1941712348.USD","LU0265550946.USD","LU0432979614.USD","LU2468319806.SGD","LU2089984988.USD","LU1934455194.USD","LU1061106388.HKD","BK4516","LU2125154778.USD","IE00BLSP4452.SGD","SG9999001176.SGD","LU0965508806.USD","SG9999014542.SGD","LU0965509101.SGD","IE00BLSP4239.USD","LU0238689110.USD","LU0477156953.USD","LU1037948897.HKD","LU0006306889.USD","IE0002141913.USD","LU1066051225.USD","LU0320765646.SGD","LU0130102774.USD","LU0122379950.USD","LU0965509283.SGD","LU2361044865.SGD","LU2461242641.AUD","SG9999001440.SGD","SG9999015358.SGD","LU2324357040.USD","LU0208291251.USD","LU0203347892.USD","SGXZ57979304.SGD","LU1989771016.USD","LU0106261372.USD","IE00B1BXHZ80.USD","LU1023059063.AUD","LU1430594728.SGD","LU1291159041.SGD","IE00B2B36J28.USD","LU2106854487.HKD","SG9999001176.USD","LU1201861249.SGD","LU0203345920.USD","LU0980610538.SGD","LU0234572021.USD","LU0098860793.USD","LU0320765489.SGD","LU0985320562.USD","LU2023250843.SGD","LU1989772840.SGD","LU1585245621.USD","LU1983299246.USD","LU1057294990.SGD","LU2360032135.SGD","IE000M9KFDE8.USD","LU1571399168.USD","BK4533","LU0266013472.USD","LU2361045086.USD","LU1066053197.SGD","IE00BBT3K403.USD","IE00BJJMRZ35.SGD","LU2125154935.USD","SG9999002232.USD","BK4550","LU0070302665.USD","SG9999014567.USD","IE0009355771.USD","LU1116320737.USD","BK4588","LU1934455863.HKD","LU1929549753.HKD","SG9999002224.SGD","BK4559","LU1989772923.USD","LU1917777945.USD","BK4585","LU0058720904.USD","LU0130517989.USD","SG9999013999.USD","RVMD","LU0965509010.AUD","LU2023250504.SGD","LU1699723380.USD","LU1162221912.USD","LU1974910355.USD","IE00BN8TJ469.HKD","LU1941712264.USD","LU0648001328.SGD","IE00BFTCPJ56.SGD","LU1093756168.USD","BK4534","IE00BSNM7G36.USD","LU0289739699.SGD","LU0265550359.USD","LU1037948541.HKD","SG9999014559.SGD","LU1116320901.HKD","SG9999014575.USD","LU0861579265.USD","LU1934455277.USD","LU1035773651.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606216851","title":"默沙东终止收购Revolution Medicines的谈判","url":"https://stock-news.laohu8.com/highlight/detail?id=2606216851","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606216851?lang=zh_cn&edition=full","pubTime":"2026-01-26 17:45","pubTimestamp":1769420700,"startTime":"0","endTime":"0","summary":"《华尔街曰报》周日报道称，美国制药巨头默沙东已终止收购抗癌药物研发企业 Revolution Medicines 的相关谈判。报道同时指出，不排除未来谈判重启的可能性，也可能会有其他企业竞购 Revolution Medicines。在非工作时间，默沙东与 Revolution Medicines 均未立即回应当路透社的置评请求。 在周一的盘前交易中，默沙东股价小幅走高，而 Revolution Medicines 的股价则暴跌 24%。 据伦敦证券交易所集团的数据显示，目前 Revolution Medicines 的市值约为 227 亿美元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-01-26/doc-inhirqaw0563971.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0265550359.USD","LU2112291526.USD","LU1934455277.USD","LU1061106388.HKD","LU1989771016.USD","LU1941712264.USD","LU1066051498.USD","LU1430594728.SGD","LU2360032135.SGD","SG9999002224.SGD","LU0980610538.SGD","LU0130102774.USD","IE00B4R5TH58.HKD","LU0098860793.USD","BK4559","LU0006306889.USD","IE00BJJMRZ35.SGD","RVMD","LU1023059063.AUD","MRK","LU1989772840.SGD","SG9999001176.SGD","LU0203347892.USD","LU2023250843.SGD","LU2089984988.USD","LU0122379950.USD","LU1057294990.SGD","SG9999001176.USD","LU0106261372.USD","LU0211331839.USD","LU1037948541.HKD","LU1035773651.USD","SG9999002232.USD","LU0648001328.SGD","LU1201861249.SGD","LU2023250504.SGD","LU0985320562.USD","LU2361044949.HKD","LU2125154935.USD","LU1989772923.USD","LU1941712348.USD","LU1066051811.HKD","LU1069347547.HKD","IE00BSNM7G36.USD","LU1093756168.USD","LU0234572021.USD","LU0203345920.USD","SG9999015341.SGD","BK4534","IE0009355771.USD","LU1116320901.HKD","BK4533","LU0432979614.USD","LU1116320737.USD","LU1291159041.SGD","LU2361044865.SGD","LU0965509101.SGD","LU0130517989.USD","LU0208291251.USD","LU1983299246.USD","LU0058720904.USD","SG9999015358.SGD","LU0320765646.SGD","LU0965509010.AUD","BK4550","LU1974910355.USD","LU1037948897.HKD","IE00BJT1NW94.SGD","LU0070302665.USD","BK4139","LU0965509283.SGD","SGXZ57979304.SGD","LU0477156953.USD","BK4007","BK4516","IE00B2B36J28.USD","LU0289739699.SGD","IE0002141913.USD","LU0238689110.USD","SG9999013999.USD","LU2106854487.HKD","LU1093756325.SGD","LU0861579265.USD","SG9999014542.SGD","LU0320765489.SGD","LU2461242641.AUD","BK4588","IE00BBT3K403.USD","LU1934455194.USD","IE000M9KFDE8.USD","LU1934455863.HKD","LU1585245621.USD","IE00BFTCPJ56.SGD","LU1066051225.USD","LU1699723380.USD","LU2468319806.SGD","IE00B1BXHZ80.USD","LU0266013472.USD","LU2125154778.USD","LU1917777945.USD","IE00BN8TJ469.HKD","IE00BLSP4452.SGD","LU0265550946.USD","SG9999014575.USD","LU1066053197.SGD","LU0965508806.USD","LU1571399168.USD","LU2361045086.USD","IE00BLSP4239.USD","LU1162221912.USD","LU1929549753.HKD","LU2324357040.USD","SG9999014559.SGD","SG9999014567.USD","SG9999001440.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181536168","title":"默克终止收购谈判消息传出 Revolution Medicines盘前股价暴跌20.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181536168","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181536168?lang=zh_cn&edition=full","pubTime":"2026-01-26 17:06","pubTimestamp":1769418371,"startTime":"0","endTime":"0","summary":"受《华尔街日报》报道默克公司已退出收购谈判影响，Revolution Medicines, Inc.股价在盘前交易中应声下挫20.7%。这一突发消息瞬间引发市场抛售潮，投资者对两家公司合作前景的预期骤然降温。目前双方均未对报道内容作出正式回应，但市场反应已清晰折射出交易搁浅对股价造成的冲击力度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606029945","title":"300亿美元生物医药并购告吹？默克转身离场，Revolution降温但故事未完","url":"https://stock-news.laohu8.com/highlight/detail?id=2606029945","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606029945?lang=zh_cn&edition=full","pubTime":"2026-01-26 14:22","pubTimestamp":1769408579,"startTime":"0","endTime":"0","summary":"默克此前曾与Revolution Medicines进行收购谈判，交易可能使这家癌症药物生物技术公司估值约为300亿美元。预计Revolution将在今年上半年发布备受关注的胰腺癌和结直肠癌药物候选产品的试验数据。不过，艾克维随后表示，\"并未与Revolution进行谈判\"。在本月早些时候的交易谈判消息曝光前，Revolution的市值约为160亿美元。Revolution正在研发针对RAS分子驱动癌症的药物。Revolution Medicines的药物候选品种有望破解这一难题。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2026/01/26142255306186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4559","LU0965509101.SGD","LU2324357040.USD","LU2125154778.USD","LU2360032135.SGD","LU0965509010.AUD","LU1699723380.USD","LU0980610538.SGD","SG9999002224.SGD","SG9999013999.USD","LU2106854487.HKD","SG9999014559.SGD","BK4588","LU1061106388.HKD","IE00BJJMRZ35.SGD","LU0098860793.USD","LU1162221912.USD","LU1035773651.USD","LU1291159041.SGD","LU0234572021.USD","SG9999014575.USD","LU0265550946.USD","LU0965509283.SGD","BK4007","SG9999001440.SGD","BK4534","LU1037948541.HKD","LU0106261372.USD","MRK","BK4585","LU1934455863.HKD","LU2089984988.USD","BK4533","BK4550","LU2023250504.SGD","LU1023059063.AUD","LU1057294990.SGD","LU0320765646.SGD","LU0648001328.SGD","LU0208291251.USD","LU1934455194.USD","SG9999014542.SGD","LU2468319806.SGD","LU1983299246.USD","SGXZ57979304.SGD","LU1116320737.USD","IE00BBT3K403.USD","LU0238689110.USD","LU0965508806.USD","LU0122379950.USD","LU0058720904.USD","LU0130517989.USD","LU0861579265.USD","BK4516","IE000M9KFDE8.USD","LU1069347547.HKD","LU0203345920.USD","LU1585245621.USD","LU1929549753.HKD","LU1066051811.HKD","IE00B4R5TH58.HKD","LU0289739699.SGD","LU0320765489.SGD","IE00BLSP4452.SGD","IE00B1BXHZ80.USD","LU1093756325.SGD","IE00BN8TJ469.HKD","LU1430594728.SGD","LU0211331839.USD","LU2125154935.USD","LU2112291526.USD","LU1974910355.USD","LU0203347892.USD","LU1037948897.HKD","IE00BSNM7G36.USD","IE00BJT1NW94.SGD","LU1201861249.SGD","SG9999001176.SGD","SG9999015341.SGD","LU2361045086.USD","LU0985320562.USD","LU1571399168.USD","LU1066051225.USD","RVMD","LU1066053197.SGD","LU1934455277.USD","LU1917777945.USD","LU0006306889.USD","LU1989772840.SGD","IE0002141913.USD","SG9999002232.USD","LU0477156953.USD","LU0070302665.USD","LU2461242641.AUD","LU1941712348.USD","IE00B2B36J28.USD","LU0266013472.USD","SG9999001176.USD","IE0009355771.USD","LU1116320901.HKD","LU1093756168.USD","SG9999014567.USD","LU0265550359.USD","LU2361044865.SGD","LU1066051498.USD","LU2361044949.HKD","LU1941712264.USD","LU1989772923.USD","LU2023250843.SGD","SG9999015358.SGD","LU1989771016.USD","LU0130102774.USD","IE00BLSP4239.USD","LU0432979614.USD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606261479","title":"夜盘异动 | Revolution重挫19%，300亿美元天价收购告吹！默沙东与Revolution因价格分歧中止谈判","url":"https://stock-news.laohu8.com/highlight/detail?id=2606261479","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606261479?lang=zh_cn&edition=full","pubTime":"2026-01-26 10:37","pubTimestamp":1769395071,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据知情人士透露，由于双方未能就收购价格达成一致，默沙东已停止收购生物技术公司Revolution Medicines的谈判。报道称，该交易原本对 Revolution Medicines 的估值可能在 300 亿美元左右。而与Revolution Medicines的交易可能使默沙东获得其实验性药物Daraxonrasib。Revolution 公司目前有多款在研化合物。据悉，Revolution Medicines正在研发的泛RAS抑制剂RMC-6236是该公司拥有的关键资产。Revolution Medicines在去年12月宣布，RASolute304临床试验已完成首例患者入组。","market":"us","thumbnail":"https://static.tigerbbs.com/a00dac9da971ee0e08b72a17d0d0b507","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a00dac9da971ee0e08b72a17d0d0b507"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397070.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"300亿美元天价收购告吹！默沙东与Revolution因价格分歧中止谈判","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0980610538.SGD","LU1066051225.USD","LU0006306889.USD","SG9999001176.SGD","LU0861579265.USD","LU0208291251.USD","BK4534","LU1037948541.HKD","LU2023250504.SGD","LU0432979614.USD","LU0477156953.USD","LU1093756325.SGD","LU0234572021.USD","IE00BSNM7G36.USD","LU1023059063.AUD","LU1291159041.SGD","LU0985320562.USD","LU1061106388.HKD","LU0238689110.USD","SG9999014559.SGD","LU0058720904.USD","LU2125154935.USD","LU1934455277.USD","LU0289739699.SGD","LU2361044865.SGD","IE0009355771.USD","LU1066051811.HKD","LU2125154778.USD","IE00BLSP4452.SGD","LU2106854487.HKD","LU2324357040.USD","LU1917777945.USD","LU1934455863.HKD","LU1201861249.SGD","SG9999002224.SGD","LU0965509283.SGD","SG9999014542.SGD","IE00BBT3K403.USD","LU0965509010.AUD","RVMD","IE00B4R5TH58.HKD","LU0266013472.USD","LU1571399168.USD","SG9999013999.USD","LU0106261372.USD","LU0648001328.SGD","LU1989771016.USD","LU2361044949.HKD","BK4588","IE00BN8TJ469.HKD","LU0203345920.USD","LU2360032135.SGD","IE00B2B36J28.USD","LU1941712264.USD","SG9999001176.USD","LU1989772840.SGD","SG9999001440.SGD","LU1430594728.SGD","LU0070302665.USD","SG9999014575.USD","IE0002141913.USD","BK4550","LU1585245621.USD","LU0965508806.USD","IE000M9KFDE8.USD","IE00BJJMRZ35.SGD","LU2468319806.SGD","SG9999015358.SGD","MRK","LU0130102774.USD","IE00B1BXHZ80.USD","LU0965509101.SGD","LU1069347547.HKD","SG9999015341.SGD","BK4139","LU0211331839.USD","SGXZ57979304.SGD","LU2089984988.USD","BK4585","SG9999002232.USD","LU2461242641.AUD","LU0130517989.USD","LU1989772923.USD","LU1116320901.HKD","LU0320765646.SGD","LU0320765489.SGD","LU1934455194.USD","LU1093756168.USD","SG9999014567.USD","LU0265550359.USD","LU1162221912.USD","BK4559","LU1929549753.HKD","IE00BLSP4239.USD","BK4516","IE00BFTCPJ56.SGD","LU0203347892.USD","LU0122379950.USD","LU1066053197.SGD","IE00BJT1NW94.SGD","BK4533","LU0098860793.USD","LU1037948897.HKD","BK4007","LU2361045086.USD","LU1116320737.USD","LU1066051498.USD","LU1941712348.USD","LU2112291526.USD","LU1983299246.USD","LU1974910355.USD","LU2023250843.SGD","LU0265550946.USD","LU1035773651.USD","LU1057294990.SGD","LU1699723380.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2603527089","title":"Revolution Medicines Inc C/Wts 17/12/2026 (To Pur Com)盘中异动 早盘股价大跌6.25%报3.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603527089","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603527089?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:31","pubTimestamp":1768228268,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日22时31分，Revolution Medicines Inc C/Wts 17/12/2026 股票出现波动，股价快速跳水6.25%。Revolution Medicines Inc C/Wts 17/12/2026 股票所在的生物技术行业中，整体跌幅为0.64%。Revolution Medicines Inc C/Wts 17/12/2026 公司简介：Revolution Medicines Inc是一家临床阶段的精密肿瘤学公司，致力于开发新颖的靶向疗法，以抑制臭名昭著的生长和生存途径内的难以捉摸的前沿靶标，尤其侧重于RAS和mTOR信号通路。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011222310997a175d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011222310997a175d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RVMDW","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602037039","title":"默沙东关注RVMD 艾伯维否认兴趣","url":"https://stock-news.laohu8.com/highlight/detail?id=2602037039","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602037039?lang=zh_cn&edition=full","pubTime":"2026-01-10 00:09","pubTimestamp":1767974940,"startTime":"0","endTime":"0","summary":"默沙东（MRK）周五早盘下跌0.3%。据英国《金融时报》报道，正洽谈以潜在数十亿美元交易收购Revolution Medicines（RVMD），此前一天艾伯维（ABBV）表示未与该生物技术公司进行讨论。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c2d46f3176d31be87e42705d65675998","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-01-10/doc-inhftucf5577600.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0265550946.USD","SGXZ57979304.SGD","LU1934455194.USD","LU2324357040.USD","IE00B2B36J28.USD","SG9999001440.SGD","LU1093756325.SGD","IE00BBT3K403.USD","IE00BLSP4452.SGD","LU1057294990.SGD","IE00BJT1NW94.SGD","LU1989772840.SGD","LU1585245621.USD","BK4534","LU1066051498.USD","BK4139","LU0965509101.SGD","LU1201861249.SGD","LU1116320901.HKD","LU2089984988.USD","LU1066051225.USD","BK4585","LU0130517989.USD","LU1066053197.SGD","LU2112291526.USD","LU0208291251.USD","LU1430594728.SGD","LU1571399168.USD","ABBV","SG9999001176.USD","BK4007","LU0965508806.USD","LU1066051811.HKD","LU1929549753.HKD","LU0106261372.USD","IE0002141913.USD","SG9999001176.SGD","IE00B4R5TH58.HKD","LU0266013472.USD","LU0861579265.USD","LU0203347892.USD","LU1116320737.USD","LU0006306889.USD","LU0058720904.USD","LU0234572021.USD","LU1934455277.USD","BK4516","BK4559","LU2461242641.AUD","LU0320765489.SGD","LU2023250504.SGD","SG9999013999.USD","BK4550","LU0211331839.USD","SG9999014542.SGD","LU0130102774.USD","LU2125154778.USD","LU1291159041.SGD","LU0320765646.SGD","LU1023059063.AUD","MRK","SG9999002232.USD","LU0070302665.USD","IE00BFTCPJ56.SGD","LU1989772923.USD","IE00B1BXHZ80.USD","LU1983299246.USD","IE0009355771.USD","LU0648001328.SGD","LU0265550359.USD","LU2023250843.SGD","LU1917777945.USD","LU1974910355.USD","LU0122379950.USD","LU0203345920.USD","RVMD","LU1069347547.HKD","LU0965509283.SGD","LU2360032135.SGD","SG9999014559.SGD","SG9999014567.USD","LU2361044865.SGD","LU1061106388.HKD","LU2361045086.USD","LU0477156953.USD","LU1162221912.USD","LU1093756168.USD","LU0985320562.USD","BK4588","IE00BJJMRZ35.SGD","LU0098860793.USD","LU1934455863.HKD","IE00BN8TJ469.HKD","SG9999014575.USD","IE000M9KFDE8.USD","LU0965509010.AUD","LU2125154935.USD","LU2468319806.SGD","SG9999002224.SGD","IE00BLSP4239.USD","LU0289739699.SGD","LU2361044949.HKD","LU1037948897.HKD","LU1037948541.HKD","SG9999015358.SGD","BK4533","LU1941712264.USD","LU0980610538.SGD","LU1989771016.USD","LU2106854487.HKD","IE00BSNM7G36.USD","SG9999015341.SGD","LU1941712348.USD","LU1699723380.USD","LU1035773651.USD","LU0238689110.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170314413","title":"盘前异动｜无人机概念股延续涨势，AgEagle涨超12%；Revolution涨超13%，传默沙东正就洽谈收购该公司","url":"https://stock-news.laohu8.com/highlight/detail?id=1170314413","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170314413?lang=zh_cn&edition=full","pubTime":"2026-01-09 17:05","pubTimestamp":1767949525,"startTime":"0","endTime":"0","summary":"1月9日，美股三大股指期货齐跌，截止发稿，道指期货跌0.07%，纳指期货跌0.05%，标普500指数期货跌0.06%。部分无人机概念股延续涨势，$AgEagle$涨超12%，$Ondas Holdings$涨近5%，$Red Cat Holdings$涨超1%；$英特尔$涨近2%，特朗普发文称与英特尔CEO进行了“不错的会面”；$Opendoor$涨超11%，特朗普宣布通过“两房”购买2000亿美元抵押贷款债券；$Revolution Medicines$涨超15%，传$默沙东$正就洽谈收购该公司，交易金额为可能在280亿至320亿美元之间。","market":"us","thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UAVS","INTC","RVMD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2602129793","title":"传获默沙东洽谈收购癌症药物开发商Revolution，交易价格或达320亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602129793","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602129793?lang=zh_cn&edition=full","pubTime":"2026-01-09 11:23","pubTimestamp":1767929007,"startTime":"0","endTime":"0","summary":"受此消息提振，截至发稿，Revolution Medicines周四美股盘后大涨超15%。不过，艾伯维随后回应称，该公司没有就收购Revolution Medicines进行谈判。Revolution Medicines在去年12月宣布，RASolute304临床试验已完成首例患者入组。根据行业研究的分析，Revolution Medicines的药物研发管线使其成为极具吸引力的收购对象。默沙东的重磅抗癌药物Keytruda将在本十年末失去专利。而与Revolution Medicines的交易可能使默沙东获得其实验性药物Daraxonrasib。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c2d46f3176d31be87e42705d65675998","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390702.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"传获默沙东洽谈收购癌症药物开发商Revolution，交易价格或达320亿美元","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["RVMD","MRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602831784","title":"美股异动｜Revolution Medicines夜盘涨超13%，传获默沙东以至多320亿美元报价洽购","url":"https://stock-news.laohu8.com/highlight/detail?id=2602831784","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602831784?lang=zh_cn&edition=full","pubTime":"2026-01-09 09:22","pubTimestamp":1767921721,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c2d46f3176d31be87e42705d65675998","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE000M9KFDE8.USD","LU0208291251.USD","RVMD","SG9999014542.SGD","LU1066053197.SGD","LU1093756325.SGD","LU1571399168.USD","LU0070302665.USD","LU1023059063.AUD","LU0130517989.USD","LU1057294990.SGD","LU1989772840.SGD","LU2125154778.USD","LU1066051498.USD","LU1201861249.SGD","LU2361044865.SGD","LU1093756168.USD","LU0648001328.SGD","LU2361044949.HKD","LU0130102774.USD","LU1037948897.HKD","LU0861579265.USD","BK4533","SG9999002224.SGD","LU0058720904.USD","SG9999001176.USD","LU2125154935.USD","LU0006306889.USD","IE00BFTCPJ56.SGD","LU1974910355.USD","LU1066051811.HKD","LU1989771016.USD","SGXZ57979304.SGD","BK4516","LU2468319806.SGD","IE00BLSP4239.USD","LU0289739699.SGD","LU1934455863.HKD","MRK","LU2360032135.SGD","LU2361045086.USD","SG9999001440.SGD","LU0234572021.USD","BK4007","LU0477156953.USD","LU0965508806.USD","LU1989772923.USD","LU0980610538.SGD","LU0965509010.AUD","LU1929549753.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118901865","title":"美股夜盘 | OPEN涨近15%， 英特尔涨近2%；RVMD涨超15%，据报默沙东正就洽谈收购","url":"https://stock-news.laohu8.com/highlight/detail?id=1118901865","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118901865?lang=zh_cn&edition=full","pubTime":"2026-01-09 09:00","pubTimestamp":1767920401,"startTime":"0","endTime":"0","summary":"1月9日，美股夜盘时段，$英特尔(INTC)$涨近2%，特朗普称与英特尔CEO进行了“不错的会面”。$Revolution Medicines(RVMD)$涨超15%，$默沙东(MRK)$据悉正洽购抗癌药开发商$Revolution Medicines(RVMD)$，交易价格或超300亿美元。美股在线房屋交易平台$Opendoor(OPEN)$涨近15%，特朗普宣布通过“两房”购买2000亿美元抵押贷款债券。$通用汽车(GM)$跌超1%，四季度因裁减电动汽车业务而计提60亿美元，非电动汽车相关计提大约11亿美元。","market":"us","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c2d46f3176d31be87e42705d65675998","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPEN","RVMD","INTC"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.revmed.com;ir.revmed.com","stockEarnings":[{"period":"1week","weight":0.0634},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.2544},{"period":"6month","weight":1.122},{"period":"1year","weight":1.8647},{"period":"ytd","weight":0.2444}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":-0.036},{"period":"3month","weight":-0.04},{"period":"6month","weight":-0.02},{"period":"1year","weight":0.1617},{"period":"ytd","weight":-0.0383}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Revolution Medicines, Inc.成立于2014年10月，是特拉华州的一家公司。该公司是一家临床阶段的精准肿瘤学公司，专注于开发靶向疗法，以抑制RAS成瘾癌症的前沿靶点。该公司拥有先进的基于结构的药物发现能力，其基础是深厚的化学生物学和癌症药理学知识以及创新的专有技术，能够创造适合非常规结合位点的小分子。该公司对癌症的遗传驱动因素和适应性耐药机制的了解，加上强大的药物发现和药物化学能力，指导建立了一个针对RAS通路和相关通路中的关键信号节点的深层管道。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.034782},{"month":2,"riseRate":0.666667,"avgChangeRate":0.00452},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.031822},{"month":4,"riseRate":0.714286,"avgChangeRate":0.047973},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.03349},{"month":6,"riseRate":0.833333,"avgChangeRate":0.042659},{"month":7,"riseRate":0.5,"avgChangeRate":-0.000709},{"month":8,"riseRate":0.666667,"avgChangeRate":0.059948},{"month":9,"riseRate":0.5,"avgChangeRate":0.038151},{"month":10,"riseRate":0.666667,"avgChangeRate":0.019949},{"month":11,"riseRate":0.833333,"avgChangeRate":0.188424},{"month":12,"riseRate":0.5,"avgChangeRate":-0.027192}],"exchange":"NASDAQ","name":"Revolution Medicines, Inc.","nameEN":"Revolution Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Revolution Medicines, Inc.(RVMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Revolution Medicines, Inc.(RVMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Revolution Medicines, Inc.,RVMD,Revolution Medicines, Inc.股票,Revolution Medicines, Inc.股票老虎,Revolution Medicines, Inc.股票老虎国际,Revolution Medicines, Inc.行情,Revolution Medicines, Inc.股票行情,Revolution Medicines, Inc.股价,Revolution Medicines, Inc.股市,Revolution Medicines, Inc.股票价格,Revolution Medicines, Inc.股票交易,Revolution Medicines, Inc.股票购买,Revolution Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Revolution Medicines, Inc.(RVMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Revolution Medicines, Inc.(RVMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}